Scope of the Heck reaction in the synthesis of of a new family of anthracene diacrylamide G-quadruplex ligands by Le Gresley, Adam et al.
The scope of the Heck reaction in the synthesis of of a new family of
anthracene diacrylamide G-quadruplex ligands
Adam Le Gresley* Ammara Abdullah, Pratchi Desai, Uttam Ghosh,
Uma Gollapalli, Munazza Kiran and Shehri Lafon
Pharmacy and Chemistry, Kingston University, Kingston upon-
Thames, Surrey, KT1 2EE, UK
Corresponding Author – a.legresley@kingston.ac.uk
Graphical Abstract
The scope of the Heck reaction in the synthesis of of a new family of
anthracene diacrylamide G-quadruplex ligands
Adam Le Gresley* Ammara Abdullah , Pratchi Desai, Uttam Ghosh,
Uma Gollapalli, Munazza Kiran and Shehri Lafon
Pharmacy and Chemistry, Kingston University, Kingston upon-
Thames, Surrey, KT1 2EE, UK
Corresponding Author – a.legresley@kingston.ac.uk
Abstract
The use of  the  Heck  reaction  in  the  synthesis  of  anthracene-9-monoacrylamide  and
anthracen-9,10-bisacrylamides   as   potential   G-quadruplex   ligands   and   preliminary
biological testing is reported.
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Introduction
The G-quadruplex can be described as the  macromolecular  structure  formed  when  a  guanine
rich oligonucleotide sequence forms several Hoogsteen bonded G-tetrads.[1] These  guanine  rich
sequences at the  end  of  chromosomes  are  termed  telomeres  and  their  depletion  in  normal
healthy somatic cells has been linked to cellular senescence, whereas their regeneration, via  the
telomerase pathway, in 90% of tumour cells has been linked to cancer cell “immortality”.[2]
 The last 10 years  has  seen  interest  in  the  exploitation  of  telomerase  mediated  tumour  cell
immortality  grow  exponentially,  with  approaches  to  inducing   telomere   mediated   apoptosis
including the  development  of  oncolytic  viruses,  vaccines  for   hTR  and  stabilising  of  the  G-
quadruplex structure, which must be “unravelled” before telomeric elongation can occur.[3]
The importance of the  G-quadruplex  structure,  which  is  formed  from  the  guanine  rich  3’  overhang  in  chromosomes,  as  an
attractive target for anticancer treatment, has been reported in a number of detailed reviews.[4]  A number of classes of G-
quadruplex ligands, ranging from acridones to porphyrins have been  reported,[5],[6],[7],[9]  however,
no G-quaduplex ligands have yet come to market.[8] In terms  of  rationalisation  of  G-quadruplex
binding, some structure-activity relationships have already  been  identified  using  assays,  NMR,
UV-vis and CD spectroscopy, include;[10]
1.         An extended planar structure to aid intercalation of the ligand in the stacked Hoogsteen bonded G-tetrads.
2.         The presence of cationic or hydrogen bonding groups to bind to the anionic phosphate backbone.
 Furthermore,  we  believe  that  any  new  class  of  compound  should  be  amenable  to  further
reversible functionalisation to increase the number and diversity of possible ligands for  screening
as exploited by Balasubraminian (DCL).[10], [11], [12]
In  light  of  the  trend  for  planar,  nitrogen  rich  species  to  have  been  shown  to  interact  with
quadruplex DNA, the anthracene diacrlyamide core found in 10 not  only  possesses  the  correct
geometry to sit between the G-tetrads, but also can undergo reversible conjugate addition with  a
range of nucleophiles.[13]
Results and Discussion
(FIGURE 1)
An anthracene unit possessing several  hydrogen  bond  donors/acceptors  was  conceived  as  a
potential G-quadruplex  ligand  and  a  series  of  anthracene  diacrylamides  possessing  various
functionalities was created in an effort to consider the scope of the Heck reaction in generating  a
suitable library and  to  understand  the  steric  and  intermolecular  bonding  that  may  affect  the
activity of this class of  ligand and how it  may  interact  both  with  duplex   and  quadruplex  DNA
motiffs.
Acrylamides
Acrylamides 4a-e,  4f, & 4k were synthesised using the method summariased in the experimental
section. Acrylamides 4g-j were obtained from Sigma-Aldrich and used without further purification.
These acrylamides were chosen to represent a broad range of polar/lipophillic binding motiffs,
Ligands
The  Heck  reaction  was  optimised  in  terms  of  ligand  (PPh3  or   DiPhenylPhosphinoPropane
-DPPP) , acrylamide ratio and anthracene precursor  as  indicated  in  table  I.  Early  attempts  to
carry out the Heck coupling using the traditional PPh3  Ligand  were  unsuccessful  (see  Table  I)
and  only  9,10-dibromoanthracene  showed  any  appreciable   reaction   within   the   timescales
indicated   in   the   presence   of   an    excess    of    acrylamide    and    the    bidentate    ligand
diphenylphosphinopropane  (DPPP).  Interestingly,  attempts  to  couple  acrylamide   4g   to   the
anthracene-9,10-ditriflate resulted in the formation of dibenzoquinone, which could  be  the  result
of hydrolysis of the triflate moiety followed by oxidation.
10 was fully characterised using 1H COSY NMR and HETCOR and  the  ?-trans  coupling  of  the
acrylamide (as evidenced by the trans olefin doublets J =15-16 Hz) is observed exclusively for all
reactions.
(TABLE I)
Efforts  to  synthesise  the  N,N-dimethyl  acrylamide  derivative  yielded  poor  results  with  trace
quantities of 5 evidenced by 1H  NMR.   In  the  case  of  9,10-dibromoanthracene  a  2:1  ratio  of
acrylamide/dibromoanthracene was shown to favour the formation  of  the  monocoupled  product
and it was necessary to use a significant  excess (6:1) of acrylamide to  achieve  80%  di-coupled
product.
The  equivalent  reaction  to  generate  13  demanded  a  significant  excess   of   acryloyl   morpholine   (8:1),
however the  good  yield  of  7/12  obtained  indicated  the  reaction  is  not  restricted  to  primary
acrylamides despite longer reaction times being required in the case of the tertiary acrylamide.
(TABLE II)
Using   the   available   acrylamides   4a-4k   and   an   optimised    Heck    reaction    with    9,10-
dibromoanthracene, a series of  anthracence  diacrylamides  were  synthesised.  acrylamides  4b
& 4d-g failed to undergo reaction within a reasonable  timeframe,  however  6,  7,  9,  10,  11,  12
& 13 were all obtained in good yield and with ?-trans coupling. It is thought  that  complexation  of
the Pd(OAc)2 catalyst especially in the case  of  4b,  4d,  &  4f  could  interfere  with  the  reaction
pathway. 8 was obtained as a mixture of mono and diacrylamide, which could not be separated.
Biological activity
After characterisation of the anthracene  diacrylamides   compounds  10  and  12  were  selected,
based on preliminary molecular modelling  data  using  Chem3D  energy  minimisation  and  their
having a Log P value of around 5.
Evaluation of 10 for anti-cancer activity in MCF7 and Caco-2 cell culture using MTT  Cell  viability
assay  indicates  no  appreciable  apoptosis  after  48  hrs  in  the  presence  of  10.  A  10  –  day
evaluation of 10 shows an IC50 value of 2.5µM and over  80%  loss  of  viability  over  the  10  day
period. Interestingly MTT viability assay of 12 in MCF7 culture shows a rapid loss of  cell  viability
over only 24hrs, with a 50% loss at concentrations as low as 5µM.  The  variation  in  the  loss  of
viable cells between the two compounds suggests a differring mode of  action  and  this  is  being
investigated further.
(FIGURE 2)
The  in  vitro  formation  of  a  tetramolecular  G–quadruplex   using    7-mer   strand   TTGGGGT
(Biomers, GmbH) has recently been reported and  has  been  visualised  using  1H  NMR,  in  the
presence and absence of a putative ligand. A 1mM concentration of  TTGGGGT  oligonucleotide,
was shown  not  to  form  a  quadruplex  in  PBS   D2O/d6-DMSO  (9:1)  over  48hrs,  however  as
evidenced by 1H NMR, a signal correlating to the tetramolecular  quadruplex  in  the  presence  of
10 was observed after only a  few  minutes,  suggesting  that  10  can  induce  and  stabilise   this
tetramolecular quadruplex.[13], [14]
(FIGURE 3)
(FIGURE 4)
Clearly duplex/quadruplex specificity needs to be investigated further and this is being carried out
  using  the  recently  reported  fluorescence  displacement  assay  and   further   confirmation   of
complexation with monomolecular G-quadruplex forming oligonucleotides is  underway,  however
the preliminary data indicates G-quadruplex stabilisation as a possible mode of action for 10  and
the negligible cytotoxic effects on endothetial cells when compared to the MCF-7 cell line and the
lack of immediate toxicity (as evidence  for  Caco-2  cell  lines)  suggests  this  class  of  ligand  is
worthy of further investigation.[14]
Conclusions
We have conducted preliminary optimisation of the conditions for  these  C-C  coupling  reactions
and the restrictions imposed on the halide and acrylamide groups  for  such  reactions  and  have
fully characterised 7 previously unreported compounds, which have the potential  not  only  to  be
potent G-quadruplex ligands but afford a route to a range of conjugate addition  products  for  the
development  of  a  G-quadruplex-templated  dynamic  combinatorial  library.  [4],  [11],  [12],  [16]  The
promotion of quadruplex DNA formation  as  observed  in  solution  by  NMR  coupled  with  initial
biological  data,  suggests  10  possesses  an  anticancer  activity,  which  renders  this  family  of
compounds  worthy  of  further  investigation  in  terms   of   both   duplex/quadruplex   selectivity,
bioavailability and expansion of the series to better understand any QSAR that may exist.
Experimental
Electronic Supplementary Information (ESI)  available:  HETCOR  ,  2D  COSY  NMR  for  10,  G-
quadruplex formation 1H NMR spectrum and general biological experimental.
1H, 13C, COSY and HETCOR NMR spectra were recorded  on  a  JEOL  ECP  400MHz.  Chemical
shifts are reported as ( values in ppm relative to TMS (( 0.00). All coupling constants  are  quoted
in Hz. Elemental analysis were made on a Leeman Labs CE440 Elemental Analyzer.
Infrared spectra were determined on a ThermoNicolet 380 FT-IR.  The  mass  spectra  (m/z)  were
recorded  on  a  Varian  CP-3800  Gas  Chromatograph  with  Varian  1200L   Quadrupole   Mass
Spectrometer.  Anthracene-9,10-ditriflate  was  synthesised  using   standard  procedure  and   all
other chemicals were purchased from the Aldrich Chemical Company.
General preparation of acrylamide precursor
N-(quinolin-6-yl)acrylamide (4c)
Et3N (8.23 ml) and the amine (27 mmol) were stirred in  DCM  75  ml  for  10  min  at  rt.  Acryloyl
chloride  (2.66  ml)  was  very  slowly  added  with  the  temperature  being  maintained  at   room
temperature. The reaction was monitored via TLC or NMR.  Upon  completion,  the  reaction  was
quenched with iced water (200 ml) and the organic component extracted with DCM (3  ×  50  ml).
The combined organic extracts were washed with HCl (3 × 40 ml, 3 M), water (2 × 50  ml)  NaOH
(3 × 30 ml, 2 M) and again with  water  (2  ×  50  ml).  The  organic  extract  was  dried  (Na2SO4),
filtered and evaporated under a reduced pressure. Solid acrylamides could be recrystalised  from
hot methanol and all acrylamides were stored below 0 ?C or used immediately.  Yields  70%  and
above – pure by tlc - characterisation data for 4c (H(400 MHz;  d6-DMSO)  10.47  (1H,  s  (broad),
NH), 8.79 (1H, dd, 3JHH = 2.5 Hz, 4JHH = 1.0, Ar-H), 8.46 (1H, d, 3JHH =  2.3  Hz,  Ar-H),  8.29  (1H,
dd, 3JHH = 7.8 Hz, 4JHH = 1.0 Hz, Ar-H), 7.99 (1H, d, 3JHH = 9.0 Hz, Ar-H), 7.88 (1H, dd, 3JHH =  9.0
Hz, 4JHH = 2.3 Hz, Ar-H),  7.49  (1H,  dd,  3JHH  =  7.8  Hz,  4JHH  =  2.5  Hz,  Ar-H),  6.52  (1H,  dd,
3JHH = 17.0 Hz, 4JHH = 10.0 Hz, COCH), 6.35 (1H, dd, 3JHH = 17.0 Hz, 4JHH = 2.0 Hz, CHaHb), 5.81
(1H, dd, 3JHH = 10.0 Hz, 4JHH = 2.0 Hz, CHaHb), (c (d6-DMSO) 164.1, 149.7,  145.4,  137.5,  136.1,
132.3, 130.1, 128.9, 127.8, 124.0, 122.4, 115.9; m/z (EI) 198[M+].
Example preparation of acrylamide
3-[10-(2-Carbamoyl-vinyl)-anthracen-9-yl]-acrylamide (10)
Triethylamine (6.6 ml, 4.81 g, 47.6 mmol) and acrylamide (3.38 g, 47.6 mmol)  were  added  to  a
stirred solution of  9,10-dibromo anthracene (2.00  g,  5.9  mmol)  in  dimethylformamide  (50  ml)
accompanied by vigorous stirring at room temperature followed by addition of  palladium  acetate
(0.27 g, 1.2 mmol) and 1,3-bis(diphenylphosphino)propane (0.49 g, 1.2 mmol). The  mixture  was
heated to 90oC for 48hrs under an atmosphere of nitrogen. The reaction was allowed to cool  and
dilute HCl (15 ml, 2M) was added. The resulting precipitate was filtered and washed with water (3
× 20 ml) and diethyl ether (3 × 15 ml) and dried under vacuum  before  being  recrystallised  from
ethanol  to  afford  the  diacrylamide  10  (1.49  g,  80  %)  as  a  yellow  powder;  mp-  338.2  °C;
(max (Nujol)/cm-1 3375 (N-H), 3200 (N-H),  1663 (C=O), 1600 (C=C); (H(400 MHz; d6-DMSO)  8.61
(4H, s (broad), NH2), 8.27 (2H, d, 3JHH = 15.8 Hz, Ar-CH=), 8.23 (4H, dd, 3JHH = 6.3 Hz, 4JHH = 2.8
Hz, Ar-H), 7.60 (4H, dd, 3JHH  =  6.3  Hz,  4JHH  =  2.8  Hz,  Ar-H),  6.41  (2H,  d,  3JHH  =  15.8  Hz,
=CHCO), (c (d6-DMSO) 166.0, 158.2,  149.4,  143.2,  142.2,  126.6,  125.8,  125.5,  123.4,  121.8,
121.4, 116.1, 72.4, 32.3, 31.4, 31.0, 19.3, 14.1; m/z (EI) 316[M+]. Found C, 75.49; H,  5.51%;  N,
8.91. C20H16N2O2 requires C, 75.93; H, 5.10%; N, 8.85%.
Characterisation
3-[10-Bromo-anthracen-9-yl]-acrylamide (6)
mp- 258.0 °C; (max (Nujol)/cm-1 3375 (N-H), 3200 (N-H),  1663 (C=O), 1600 (C=C); (H(400 MHz;
d6-DMSO) 8.50 (2H, d, 3JHH = 8.8 Hz, Ar-H), 8.26 (1H, d, 3JHH = 16.1 Hz), 8.24 (2H, d, 3JHH = 8.8
Hz, Ar-H), 7.76 (4H, ddd, 3JHH = 8.9 Hz, 3JHH = 6.4 Hz, 4JHH = 0.9 Hz, Ar-H), 7.66 (4H, ddd, 3JHH =
8.9 Hz, 3JHH = 6.4 Hz, 4JHH = 0.9 Hz, Ar-H),  7.41 (2H, s (broad), NH2), 6.46 (1H, d, 3JHH = 16.1
Hz, =CHCO), (c (d6-DMSO)166.0, 141.5, 134.9, 129.5, 129.4, 129.3, 128.3, 128.6, 127.3, 126.3
m/z (EI) 326 [M+]. Found C, 61.89; H, 3.72%; N, 4.18%. C17H12BrNO requires C, 62.60%; H,
3.71%; 4.29%.
3-[10-Bromo-anthracen-9-yl]-acryloylmorpholine (7)
mp- 278.2 °C; (max (Nujol)/cm-1 1663 (C=O), 1600 (C=C);  (H(400  MHz;  d6-DMSO)  8.48  (2H,  d,
3JHH = 8.6 Hz, Ar-H), 8.31 (2H, d, 3JHH = 15.7 Hz, Ar-CH=), 8.20  (2H,  d,  3JHH  =  8.6  Hz,  Ar-H)  ,
7.64 (2H, ddd, 3JHH = 10.0 Hz,  3JHH = 5.2 Hz, 4JHH = 1.1 Hz, Ar-H), 7.54 (2H, ddd, 3JHH = 10.0 Hz,
 3JHH = 5.2 Hz, 4JHH = 1.1 Hz,  Ar-H),  6.93(2H,  d,  3JHH  =  15.7  Hz,  =CHCO),  3.54-3.60  (16H,  m,
OCH2CH2N). (c (d6-DMSO) 166.3, 145.4, 139.3, 138.2, 131.8, 127.7, 127.6, 126.7,  126.5,  121.8,
121.4, 126.3,  125.9,  43.0  30.5;  m/z  (EI)  393[M+].  Found  C,  63.89%;  H,  4.07%;  N,  3.72%.
C21H16NO2Br requires C, 64.12%; H, 4.07%; N, 3.56%.
(2E,2’E)-3,3’-(anthracene-9,10-diyl)bis(1-(piperidin-1-yl)prop-2-en-1-one) (8)
mp- 294.4 °C; (max  (Nujol)/cm-1  1660  (C=O),  1600  (C=C);  (H(400  MHz;  CDCl3)  8.53  (2H,  d,
3JHH = 15.6 Hz, Ar-CH=), 8.28 (4H, dd, 3JHH = 6.8 Hz, 4JHH = 3.3 Hz, Ar-H), 7.50  (4H,  dd,  3JHH  =
6.8 Hz, 4JHH = 3.3 Hz, Ar-H), 6.84 (2H, d, 3JHH = 15.6 Hz, =CHCO), 3.77  (4H,  m,  NCHaHb),  3.55
(4H, m, NCHaHb), 1.70 (8H, m, NCHaHbCH2), 1.61 (4H,  m,  NCHaHbCH2CH2);  (c  (CDCl3)  164.1,
138.2, 132.0, 129.0, 128.7, 126.5, 126.2, 46.9, 43.2, 24.7; m/z (EI)  452[M+].  Found  C,  80.09%;
H, 6.92%; N, 5.70%. C30H32N2O2 requires C, 79.64%; H, 7.08%; N, 6.19%.
(2E,2’E)-3,3’-(anthracene-9,10-diyl)bis(N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl)acrylamide) (11)
mp- 250.2 °C; (max (Nujol)/cm-1 3400 (OH), 3250 (N-H),  1660 (C=O), 1600  (C=C);  (H(400  MHz;
d6-DMSO) 9.04 (2H, s (broad), NH), 8.25 (2H, d, 3JHH = 16.0 Hz, Ar-CH=),  8.23  (4H,  dd,  3JHH  =
6.5 Hz, 4JHH = 3.3 Hz, Ar-H), 7.59 (4H, dd, 3JHH  =  6.5  Hz,  4JHH  =  3.3  Hz,  Ar-H),  6.68  (2H,  d,
3JHH = 16.0 Hz, =CHCO), 4.84 (6H, t, 3JHH = 5.8 Hz, OH), 3.68 (12H, d,  3JHH  =  5.8  Hz,  CH2),  (c
(d6-DMSO) 165.7, 135.6, 132.6, 131.7, 129.0, 126.8, 126.4, 63.5, 61.0; m/z  (EI)  524[M+].  Found
C, 63.89; H, 5.92%; N, 5.69. C28H32N2O8 requires C, 64.12; H, 6.11%; N, 5.34%.
(2E,2’E)-3,3’-(anthracene-9,10-diyl)bis(1-morpholinoprop-2-en-1-one) (12)
mp-  255  °C;  (max  (Nujol)/cm-1  1660  (C=O),  1600  (C=C);  (H(400  MHz;  CDCl3)  8.63  (2H,  d,
3JHH = 15.6 Hz, Ar-CH=), 8.26 (4H, dd, 3JHH = 7.0 Hz, 4JHH = 3.1 Hz, Ar-H), 7.52  (4H,  dd,  3JHH  =
7.0 Hz, 4JHH = 3.1 Hz,  Ar-H),  6.79  (2H,  d,  3JHH  =  15.6  Hz,  =CHCO),  3.80  (16H,  m  (broad),
NCH2CH2O),  (c  (d6-DMSO)  164.9,  140.8,  132.0,  128.9,  126.0,  66.8,   46.2,   42.6;   m/z   (EI)
479[M+Na]. Found C, 74.06; H, 5.92%; N, 5.92. C28H28N2O4 requires  C,  73.68%;  H,  6.14%;  N,
6.14%.
(2E,2’E)-3,3’-(anthracene-9,10-diyl)bis(N-phenylacrylamide) (13)
mp- 368.5 °C; (max (Nujol)/cm-1 3300 (N-H), 1663  (C=O),  1600  (C=C);  (H(400  MHz;  d6-DMSO)
10.40(2H, s (broad), NH), 8.50 (2H, d, 3JHH = 15.9  Hz,  Ar-CH=),  8.23  (4H,  dd,  3JHH  =  6.8  Hz,
4JHH = 3.3 Hz, Ar-H), 7.79 (4H, d, 3JHH = 7.6 Hz,  Ar-H  (Aniline)),  7.66  (4H,  dd,  3JHH  =  6.8  Hz,
4JHH = 3.3 Hz, Ar-H), 7.39 (4H, t, 3JHH = 7.6 Hz, Ar-H (Aniline)), 7.13 (4H, t, 3JHH  =  7.6  Hz,  Ar-H
(Aniline)), 6.75(2H, d, 3JHH = 15.9 Hz, =CHCO), (c (d6-DMSO) 164.1, 155.9,  149.4,  134.0,  132.5,
132.1, 129.7, 128.9, 127.1, 125.4 121.8, 121.4; m/z (EI) 468[M+]. Found  C,  81.87%;  H,  5.51%;
N, 5.69%. C32H24N2O2 requires C, 82.05%; H, 5.13%; N, 5.98%.
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Figure. 1 Reaction scheme for acylamide and anthacene diacrylamide synthesis (4g, 4h, 4i &  4j
were obtained from Sigma-Aldrich)
|SM(c|Ligand|Ratio(|Acrylamide|Duration    |Product     |Yield   |
|)   |      |d)    |          |(Hrs)       |(ratio)     |(%)     |
|1   |PPh3  |2:1   |g         |130         |-           |0       |
|1   |DPPP  |2:1   |g         |130         |-           |0       |
|1   |DPPP  |2:1   |h         |125         |5           |5       |
|2   |PPh3  |2:1   |h         |120         |5           |10      |
|2   |DPPP  |2:1   |g         |150         |4           |5       |
|2   |DPPP  |2:1   |h         |64          |5           |75      |
|3   |PPh3  |2:1   |h         |120         |- (a)       |-       |
|3   |DPPP  |2:1   |h         |120         |-(a)        |-       |
|2   |DPPP  |4:1   |h         |72          |5 & 9       |30(b)   |
|    |      |      |          |            |(1:2.3)     |        |
|2   |DPPP  |6:1   |h         |72          |5 & 9       |70(b)   |
|    |      |      |          |            |(1:4)       |        |
|2   |DPPP  |8:1   |h         |48          |9           |80      |
|2   |DPPP  |4:1   |j         |86          |6           |71      |
|2   |DPPP  |8:1   |j         |96          |6 & 11 (3:1)|73(b)   |
Table I. Optimisation of Heck reaction. (a)Dibenzoquinone was isolated as the sole product.  (b)the
yield  is  given  as  the   combined   yield   of   products.(c)SM:   starting   anthracene.   (d)Ratio   of
Acrylamide:SM
|Acrylamide|Duration     |Product      |Yield (%)       |
|          |(Hrs)        |(ratio)      |                |
|4a        |72           |7            |58              |
|4b        |150          |-            |-               |
|4c        |150          |8            |Mixture –       |
|          |             |             |mono/di         |
|4d        |150          |-            |-               |
|4e        |150          |-            |-               |
|4f        |150          |-            |-               |
|4i        |124          |10           |74              |
|4j        |110          |11           |81              |
|4k        |118          |12           |69              |
Table 2. Reaction data for acrylamides (8:1 ratio) 4a-f, 4i & 4j with 2.
Figure 2. Dose response curves for MCF7  cell  line  at  24hrs,  5  days  and  10  days  for  10  in
(PBS/0.1% v/v DMSO)
Figure 3. Showing cell viability after 48hrs for Caco-2 cell line for range  of  concentrations  of  10
(PBS / 0.1% v/v DMSO)
Figure 4. Showing cell viability after 24hrs for MCF-7 cell line for range  of  concentrations  of  12
(PBS / 0.1% v/v DMSO)
